The role of CDK4/6 inhibitors in early breast cancer

por Gil-Gil, Miguel, Alba, Emilio, Gavilá, Joaquín, de la Haba-Rodríguez, Juan, Ciruelos, Eva, Tolosa, Pablo, Candini, Daniele, Llombart-Cussac, Antonio
Publicado no Breast (2021)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy

por Herrero-Vicent, Carmen, Guerrero, Angel, Gavilá, Joaquin, Gozalbo, Francisco, Hernández, Abraham, Sandiego, Sergio, Algarra, Maria Asunción, Calatrava, Ana, Guillem-Porta, Vicente, Ruiz-Simón, Amparo
Publicado no Ecancermedicalscience (2017)

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

por Garcia-Casado, Zaida, Guerrero-Zotano, Angel, Llombart-Cussac, Antonio, Calatrava, Ana, Fernandez-Serra, Antonio, Ruiz-Simon, Amparo, Gavila, Joaquin, Climent, Miguel A, Almenar, Sergio, Cervera-Deval, Jose, Campos, Josefina, Albaladejo, Carlos Vazquez, Llombart-Bosch, Antonio, Guillem, Vicente, Lopez-Guerrero, Jose A
Publicado em 2010

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

por Pajares, Bella, Pollán, Marina, Martín, Miguel, Mackey, John R, Lluch, Ana, Gavila, Joaquín, Vogel, Charles, Ruiz-Borrego, Manuel, Calvo, Lourdes, Pienkowski, Tadeusz, Rodríguez-Lescure, Álvaro, Seguí, Miguel Angel, Tredan, Olivier, Antón, Antonio, Ramos, Manuel, Cámara, María del Carmen, Rodríguez-Martín, César, Carrasco, Eva, Alba, Emilio
Publicado em 2013

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt...

por Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A., Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C., Llombart-Cussac, Antonio, Prat, Aleix
Publicado no BMC Med (2019)

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cance...

por Llombart-Cussac, Antonio, Bermejo, Begoña, Villanueva, Cristian, Delaloge, Suzette, Morales, Serafín, Balmaña, Judith, Amillano, Kepa, Bonnefoi, Hervé, Casas, Ana, Manso, Luis, Roché, Henri, Gonzalez-Santiago, Santiago, Gavilá, Joaquín, Sánchez-Rovira, Pedro, Di Cosimo, Serena, Harbeck, Nadia, Charpentier, Eric, Garcia-Ribas, Ignacio, Radosevic-Robin, Nina, Aura, Claudia, Baselga, Jose
Publicado no Breast Cancer Res Treat (2015)

Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy

por Pascual, Tomás, Fernandez-Martinez, Aranzazu, Tanioka, Maki, Dieci, M. Vittoria, Pernas, Sonia, Gavila, Joaquin, Guarnieri, Valentina, Cortes, Javier, Villagrasa, Patricia, Chic, Núria, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Griguolo, Gaia, Llombart, Antonio, Conte, Pierfranco, Oliveira, Mafalda, Conte, Benedetta, Paré, Laia, Galvan, Patricia, Carey, Lisa A., Perou, Charles M., Prat, Aleix
Publicado no Clin Cancer Res (2021)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy

por Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix
Publicado no EBioMedicine (2021)

ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors

por Guerrero-Zotano, Angel L., Stricker, Thomas P., Formisano, Luigi, Hutchinson, Katherine E., Stover, Daniel G., Lee, Kyung-min, Schwarz, Luis J., Giltnane, Jennifer M., Estrada, Valeria M., Jansen, Valerie M., Servetto, Alberto, Gavilá, Joaquín, Perez-Fidalgo, J. Alejandro, Lluch, Ana, Llombart, Antonio, Bayar, Mohamed A., Michiels, Stefan, André, Fabrice, Arnedos, Mónica, Guillem, Vicente, Ruiz, Amparo, Arteaga, Carlos L.
Publicado no Clin Cancer Res (2018)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

por Garrido-Castro, Ana C., Saura, Cristina, Barroso-Sousa, Romualdo, Guo, Hao, Ciruelos, Eva, Bermejo, Begoña, Gavilá, Joaquin, Serra, Violeta, Prat, Aleix, Paré, Laia, Céliz, Pamela, Villagrasa, Patricia, Li, Yisheng, Savoie, Jennifer, Xu, Zhan, Arteaga, Carlos L., Krop, Ian E., Solit, David B., Mills, Gordon B., Cantley, Lewis C., Winer, Eric P., Lin, Nancy U., Rodon, Jordi
Publicado no Breast Cancer Res (2020)

Correction: ER(+) Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

por Guerrero-Zotano, Angel L., Stricker, Thomas P., Formisano, Luigi, Hutchinson, Katherine E., Stover, Daniel G., Lee, Kyung-Min, Schwarz, Luis J., Giltnane, Jennifer M., Estrada, Monica V., Jansen, Valerie M., Servetto, Alberto, Gavilá, Joaquín, Perez-Fidalgo, J. Alejandro, Lluch, Ana, Llombart-Cussac, Antonio, Bayar, Mohamed Amine, Michiels, Stefan, André, Fabrice, Arnedos, Mόnica, Guillem, Vicente, Ruiz-Simon, Amparo, Arteaga, Carlos L.
Publicado no Clin Cancer Res (2019)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

por Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix
Publicado no NPJ Breast Cancer (2021)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

por Bellet, Meritxell, Ahmad, Faten, Villanueva, Rafael, Valdivia, Carolina, Palomino-Doza, Julián, Ruiz, Ada, Gonzàlez, Xavier, Adrover, Encarna, Azaro, Analía, Valls-Margarit, Maria, Parra, Josep Lluís, Aguilar, Juan, Vidal, Maria, Martín, Anastasi, Gavilá, Joaquín, Escrivá-de-Romaní, Santiago, Perelló, Antonia, Hernando, Cristina, Lahuerta, Ainhara, Zamora, Pilar, Reyes, Victoria, Alcalde, María, Masanas, Helena, Céliz, Pamela, Ruíz, Isabel, Gil, Miguel, Seguí, Miguel Àngel, de la Peña, Lorena
Publicado no Ther Adv Med Oncol (2019)

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

por Pascual, Tomás, Oliveira, Mafalda, Ciruelos, Eva, Bellet Ezquerra, Meritxell, Saura, Cristina, Gavilá, Joaquin, Pernas, Sonia, Muñoz, Montserrat, Vidal, Maria J., Margelí Vila, Mireia, Cejalvo, Juan M., González-Farré, Blanca, Espinosa-Bravo, Martin, Cruz, Josefina, Salvador-Bofill, Francisco Javier, Guerra, Juan Antonio, Luna Barrera, Ana María, Arumi de Dios, Miriam, Esker, Stephen, Fan, Pang-Dian, Martínez-Sáez, Olga, Villacampa, Guillermo, Paré, Laia, Ferrero-Cafiero, Juan M., Villagrasa, Patricia, Prat, Aleix
Publicado no Front Oncol (2021)